Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): Updated guidelines of the Infectious DiseasesWorking Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 21-33

  Maschmeyer, Georg ^a   Carratala J ^b   Buchheidt, D ^c   Hamprecht, A ^d   Heussel, C P ^e   Kahl, C ^f   Lorenz, J ^g   Neumann, S ^h   Rieger, C ⁱ   Ruhnke, M ^j   Salwender, H ^k   Schmidt Hieber, M ^l   Azoulay, E ^m  

^a KLINIKUM ERNST VON BERGMANN   (Germany)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f Klinikum Magdeburg   (Germany)

^g Klinikum Ludenscheid   (Germany)

^h Medical Oncology   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k ASKLEPIOS KLINIK ALTONA   (Germany)

^l HELIOS KLINIKUM BERLIN BUCH   (Germany)

^m SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Diagnosis; Fever; Lung infiltrates; Neutropenia; Pneumonia; Treatment

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; ATOVAQUONE; BETA LACTAM; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPTOMYCIN; DEFERASIROX; ECHINOCANDIN; FLUCLOXACILLIN; FOSCARNET; GANCICLOVIR; LINEZOLID; MACROLIDE; MEROPENEM; OXACILLIN; PENTAMIDINE; PIPERACILLIN; PRIMAQUINE; TIGECYCLINE; VANCOMYCIN; VORICONAZOLE; ANTIINFECTIVE AGENT; DRUG COMBINATION; SULFADOXINE; TRIMETHOPRIM; TRIMETHOPRIM, SULFADOXINE DRUG COMBINATION;

ACUTE LEUKEMIA; ALGORITHM; ANTIMICROBIAL THERAPY; ARTICLE; BRONCHOSCOPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CT GUIDED PERCUTANEOUS SIDE CUT CORE NEEDLE BIOPSY; CYTOMEGALOVIRUS PNEUMONIA; DRUG MEGADOSE; FEBRILE NEUTROPENIA; GENE AMPLIFICATION; GERMANY; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; INTENSIVE CARE; LUNG ANGIOGRAPHY; LUNG INFILTRATE; LUNG LAVAGE; LUNG MYCOSIS; MEDICAL SOCIETY; MICROBIOLOGY; MUCORMYCOSIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN LUNG BIOPSY; PERCUTANEOUS BIOPSY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PSEUDOMONAS PNEUMONIA; RECOMMENDED DRUG DOSE; STAPHYLOCOCCAL PNEUMONIA; STENOTROPHOMONAS MALTOPHILIA PNEUMONIA; THORAX RADIOGRAPHY; URINALYSIS; BRONCHOALVEOLAR LAVAGE FLUID; DRUG COMBINATION; FEVER; LUNG; LUNG DISEASES; NEUTROPENIA; PARASITOLOGY; SUPPURATION; VIROLOGY;

ANTI-INFECTIVE AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DRUG COMBINATIONS; FEVER; HUMANS; LUNG; LUNG DISEASES; NEUTROPENIA; SULFADOXINE; SUPPURATION; TRIMETHOPRIM;

EID: 84922241121     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu192     Document Type: Article

References (173)

1. Einsele H, Bertz H, Beyer J et al. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82(Suppl 2): S175-S185.
2. Korones DN. Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer 2004; 43: 715-717.
3. Navigante AH, Cerchietti LC, Costantini P et al. Conventional chest radiography in the initial assessment of adult cancer patients with fever and neutropenia. Cancer Control 2002; 9: 346-351.
4. Oude Nijhuis CS, Gietema JA, Vellenga E et al. Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients. Eur J Cancer 2003; 39: 2495-2498.
5. Heussel CP, Kauczor HU, Heussel G et al. Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT. Am J Roentgenol 1997; 169: 1347-1353.
6. Heussel CP, Kauczor HU, Heussel GE et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999; 17: 796-805.
7. Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect 2001; 7(Suppl 2): 54-61.
8. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52: 1144-1155.
9. Rámila E, Sureda A, Martino R et al. Bronchoscopy guided by high-resolution computed tomography for the diagnosis of pulmonary infections in patients with hematologic malignancies and normal plain chest X-ray. Haematologica 2000; 85: 961-966.
10. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
11. Cornillet A, Camus C, Nimubona S et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43: 577-584.
12. Godoy MC, Viswanathan C, Marchiori E et al. The reversed halo sign: update and differential diagnosis. Br J Radiol 2012; 85: 1226-1235.
13. Suzuki HI, Asai T, Tamaki Z et al. Drug-induced hypersensitivity syndrome with rapid hematopoietic reconstitution during treatment for acute myeloid leukemia. Haematologica 2008; 93: 469-470.
14. Caillot D, Latrabe V, Thiébaut A et al. Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: a useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol 2010; 74: e172-e175.
15. Escuissato DL, Gasparetto EL, Marchiori E et al. Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients. Am J Roentgenol 2005; 185: 608-615.
16. Gasparetto EL, Escuissato DL, Marchiori E et al. High-resolution CT findings of respiratory syncytial virus pneumonia after bone marrow transplantation. Am J Roentgenol 2004; 182: 1133-1137.
17. Hachem R, Sumoza D, Hanna H et al. Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group criteria be revised? Cancer 2006; 106: 1581-1586.
18. Heussel CP, Kauczor HU, Ullmann AJ. Pneumonia in neutropenic patients. Eur Radiol 2004; 14: 256-271.
19. Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia: highresolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol 2012; 198: W555-W561.
20. Tasaka S, Tokuda H, Sakai F et al. Comparison of clinical and radiological features of Pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med 2010; 49: 273-281.
21. Vogel MN, Vatlach M, Weissgerber P et al. HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol 2012; 81: 1315-1320.
22. Georgiadou SP, Kontoyiannis DP. Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis? J Infect 2012; 65: 262-268.
23. Shorr AF, Susla GM, O'Grady NP. Pulmonary infiltrates in the non-HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes. Chest 2004; 125: 260-271.
24. Sonnet S, Buitrago-Téllez CH, Tamm M et al. Direct detection of angioinvasive pulmonary aspergillosis in immunosuppressed patients: preliminary results with high-resolution 16-MDCT angiography. AJR Am J Roentgenol 2005; 184: 746-751.
25. Stanzani M, Battista G, Sassi C et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis 2012; 54: 610-616.
26. Attenberger UI, Morelli JN, Henzler T et al. 3Tesla proton MRI for the diagnosis of pneumonia/lung infiltrates in neutropenic patients with acute myeloid leukemia: initial results in comparison to HRCT. Eur J Radiol 2014; 83: e61-e66.
27. Eibel R, Herzog P, Dietrich O et al. Pulmonary abnormalities in immunocompromised patients: comparative detection with parallel acquisition MR imaging and thin-section helical CT. Radiology 2006; 241: 880-891.
28. Vos FJ, Donnelly JP, Oyen WJ et al. 18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging 2012; 39: 120-128.
29. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-259.
30. Brodoefel H, Vogel M, Hebart H et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis. Am J Roentgenol 2006; 187: 404-413.
31. Ellis ME, Spence D, Bouchama A et al. Open lung biopsy provides a higher and more specific diagnostic yield compared to bronchoalveolar lavage in immunocompromised patients. Scand J Infect Dis 1995; 27: 157-162.
32. Azoulay E, Mokart D, Rabbat A et al. Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure. Crit Care Med 2008; 36: 100-107.
33. Hummel M, Rudert S, Hof H et al. Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates. Ann Hematol 2008; 87: 291-297.
34. Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 2007; 45: 228-233.
35. Dettenkofer M, Wenzler-Rottele S, Babikir R et al. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant. Clin Infect Dis 2005; 40: 926-931.
36. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-989.
37. Sharma S, Nadrous HF, Peters SG et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005; 128: 1385-1392.
38. Perfect JR, Cox GM, Lee JY et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33: 1824-1833.
39. Azoulay E, Mokart D, Lambert J et al. Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med 2010; 182: 1038-1046.
40. Boersma WG, Erjavec Z, van der Werf TS et al. Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with hematologic malignancies: BAL versus PSB and PBAL. Respir Med 2007; 101: 317-325.
41. Jain P, Sandur S, Meli Y et al. Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates. Chest 2004; 125: 712-722.
42. Zihlif M, Khanchandani G, Ahmed HP, Soubani AO. Surgical lung biopsy in patients with hematological malignancy or hematopoietic stem cell transplantation and unexplained pulmonary infiltrates: improved outcome with specific diagnosis. Am J Hematol 2005; 78: 94-99.
43. Mulabecirovic A, Gaulhofer P, Auner HW et al. Pulmonary infiltrates in patients with haematologic malignancies: transbronchial lung biopsy increases the diagnostic yield with respect to neoplastic infiltrates and toxic pneumonitis. Ann Hematol 2004; 83: 420-422.
44. Patel NR, Lee PS, Kim JH et al. The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients. Chest 2005; 127: 1388-1396.
45. Peikert T, Rana S, Edell ES. Safety, diagnostic yield, and therapeutic implications of flexible bronchoscopy in patients with febrile neutropenia and pulmonary infiltrates. Mayo Clin Proc 2005; 80: 1414-1420.
46. Shah AA, Hazen KC. Diagnostic accuracy of histopathologic and cytopathologic examination of Aspergillus species. Am J Clin Pathol 2013; 139: 55-61.
47. Daniels CE, Myers JL, Utz JP et al. Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion. Respir Med 2007; 101: 162-168.
48. Camus P, Costabel U. Drug-induced respiratory disease in patients with hematological diseases. Semin Respir Crit Care Med 2005; 26: 458-481.
49. Armenian SH, La Via WV, Siegel SE, Mascarenhas L. Evaluation of persistent pulmonary infiltrates in pediatric oncology patients. Pediatr Blood Cancer 2007; 48: 165-172.
50. Theodore S, Liava'a M, Antippa P et al. Surgical management of invasive pulmonary fungal infection in hematology patients. Ann Thorac Surg 2009; 87: 1532-1538.
51. Georgiadou SP, Sampsonas FL, Rice D et al. Open-lung biopsy in patients with undiagnosed lung lesions referred at a tertiary cancer center is safe and reveals noncancerous, noninfectious entities as the most common diagnoses. Eur J Clin Microbiol Infect Dis 2013; 32: 101-105.
52. White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. Am J Respir Crit Care Med 2000; 161: 723-729.
53. Hoffer FA, Gow K, Flynn PM, Davidoff A. Accuracy of percutaneous lung biopsy for invasive pulmonary aspergillosis. Pediatr Radiol 2001; 31: 144-152.
54. Carrafiello G, Lagana D, Nosari AM et al. Utility of computed tomography and of fine needle aspiration biopsy in early diagnosis of fungal pulmonary infections. Radiol Med 2006; 111: 33-41.
55. Gupta S, Sultenfuss M, Romaguera JE et al. CT-guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions. Hematol Oncol 2010; 28: 75-81.
56. Lass-Flörl C, Resch G, Nachbaur D et al. The value of computed tomographyguided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45: e101-e104.
57. Reinwald M, Spiess B, Heinz WJ et al. Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive Aspergillosis enhances diagnostic capabilities. J Clin Microbiol 2013; 51: 4178-4185.
58. Rickerts V, Mousset S, Lambrecht E et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007; 44: 1078-1083.
59. Manhire A, Charig M, Clelland C et al. Guidelines for radiologically guided lung biopsy. Thorax 2003; 58: 920-936.
60. Chemaly RF, Hanmod SS, Rathod DB et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 2012; 119: 2738-2745.
61. Hirsch HH, Martino R, Ward KN et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013; 56: 258-266.
62. Debur MC, Vidal LR, Stroparo E et al. Human metapneumovirus infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis 2010; 12: 173-179.
63. Williams JV, Martino R, Rabella N et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis 2005; 192: 1061-1065.
64. Hohenthal U, Itälä M, Salonen J et al. Bronchoalveolar lavage in immunocompromised patients with haematological malignancy-value of new microbiological methods. Eur J Haematol 2005; 74: 203-211.
65. Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program 2011; 2011: 305-309.
66. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
67. Sing A, Trebesius K, Roggenkamp A et al. Evaluation of diagnostic value and epidemiological implications of PCR for Pneumocystis carinii in different immunosuppressed and immunocompetent patient groups. J Clin Microbiol 2000; 38: 1461-1467.
68. Ponce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010; 50: 347-353.
69. Lu Y, Ling G, Qiang C et al. PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol 2011; 49: 4361-4363.
70. Azoulay E, Bergeron A, Chevret S et al. Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009; 135: 655-661.
71. Alanio A, Desoubeaux G, Sarfati C et al. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 2011; 17: 1531-1537.
72. Hardak E, Neuberger A, Yigla M et al. Outcome of Pneumocystis jirovecii pneumonia diagnosed by polymerase chain reaction in patients without human immunodeficiency virus infection. Respirology 2012; 17: 681-686.
73. Mühlethaler K, Bögli-Stuber K, Wasmer S et al. Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J 2012; 39: 971-978.
74. Onishi A, Sugiyama D, Kogata Y et al. Diagnostic accuracy of serum 1,3-β-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 2012; 50: 7-15.
75. Theel ES, Jespersen DJ, Iqbal S et al. Detection of (1, 3)-β-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia 2013; 175: 33-41.
76. Karageorgopoulos DE, Qu JM, Korbila IP et al. Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect 2013; 19: 39-49.
77. Busca A, Locatelli F, Barbui A et al. Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc 2006; 38: 1610-1613.
78. Einsele H, Hebart H, Roller G et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997; 35: 1353-1360.
79. Maertens J, Verhaegen J, Demuynck H et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223-3228.
80. Maertens JA, Klont R, Masson C et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44: 1329-1336.
81. Spiess B, Buchheidt D, Baust C et al. Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients. J Clin Microbiol 2003; 41: 1811-1818.
82. Zou M, Tang L, Zhao S et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One 2012; 7: e43347.
83. Becker MJ, Lugtenburg EJ, Cornelissen JJ et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121: 448-457.
84. Buchheidt D, Baust C, Skladny H et al. Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results. Clin Infect Dis 2001; 33: 428-435.
85. Weisser M, Rausch C, Droll A et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 2005; 41: 1143-1149.
86. Aubry A, Porcher R, Bottero J et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006; 44: 389-394.
87. Boonsarngsuk V, Niyompattama A, Teosirimongkol C, Sriwanichrak K. Falsepositive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand J Infect Dis 2010; 42: 461-468.
88. Girmenia C, Santilli S, Ballarò D et al. Enteral nutrition may cause false-positive results of Aspergillus galactomannan assay in absence of gastrointestinal diseases. Mycoses 2011; 54: e883-e884.
89. Tortorano AM, Esposto MC, Prigitano A et al. Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 2012; 50: 1051-1053.
90. Hage CA, Reynolds JM, Durkin M et al. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol 2007; 45: 676-677.
91. Martín-Rabadán P, Gijón P, Alonso Fernández R et al. False-positive Aspergillus antigenemia due to blood product conditioning fluids. Clin Infect Dis 2012; 55: e22-e27.
92. Johnson GL, Sarker SJ, Hill K et al. Significant decline in galactomannan signal during storage of clinical serum samples. Int J Mol Sci 2013; 14: 12970-7.
93. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1,3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659.
94. Ruhnke M, Böhme A, Buchheidt D et al. Diagnosis of invasive fungal infections in hematology and oncology guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 2012; 23: 823-833.
95. Lass-Flörl C, Gunsilius E, Gastl G et al. Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol 2004; 42: 4154-4157.
96. Ljungman P, von Dobeln L, Ringholm L et al. The value of CMV and fungal PCR for monitoring for acute leukaemia and autologous stem cell transplant patients. Scand J Infect Dis 2005; 37: 121-127.
97. Musher B, Fredricks D, Leisenring W et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42: 5517-5522.
98. White PL, Bretagne S, Klingspor L et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010; 48: 1231-1240.
99. Mengoli C, Cruciani M, Barnes RA et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 89-96.
100. White PL, Linton CJ, Perry MD et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479-486.
101. Avni T, Levy I, Sprecher H et al. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. J Clin Microbiol 2012; 50: 3652-3658.
102. Heng SC, Morrissey O, Chen SC et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol 2013 June 25 [epub ahead of print], doi: 10.3109/1040841X.2013.804033.
103. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-1769.
104. McCulloch E, Ramage G, Rajendran R et al. Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis. J Clin Pathol 2012; 65: 83-86.
105. Gudiol C, Verdaguer R, Angeles Domínguez M et al. Outbreak of Legionnaires' disease in immunosuppressed patients at a cancer centre: usefulness of universal urine antigen testing and early levofloxacin therapy. Clin Microbiol Infect 2007; 13: 1125-1128.
106. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A et al. Markers of bacteremia in febrile neutropenic patients with haematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004; 23: 539-544.
107. Monneret G, Doche C, Durand DV et al. Procalcitonin as a specific marker of bacterial infection in adults. Clin Chem Lab Med 1998; 36: 67-68.
108. Robinson JO, Lamoth F, Bally F et al. Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One 2011; 6: e18886.
109. Maschmeyer G, Heinz WJ, Hertenstein B et al. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. Eur J Clin Microbiol Infect Dis 2013; 32: 679-689.
110. Kish MA, Infectious Diseases Society of America. Guide to development of practice guidelines. Clin Infect Dis 2001; 32: 851-854.
111. Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. Cancer 2011; 117: 3424-3433.
112. Carratalà J, Rosón B, Fernández-Sevilla A et al. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med 1998; 158: 868-872.
113. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
114. Schiel X, Link H, Maschmeyer G et al. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients. Infection 2006; 34: 118-126.
115. Cornely OA, Maertens J, Bresnik M et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2011; 54: e449-e455.
116. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-379.
117. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003; 326: 1111-1119.
118. Ainoda Y, Hirai Y, Fujita T et al. Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia. J Infect Chemother 2012; 18: 722-728.
119. Roger PM, Vandenbos F, Pugliese P et al. Persistence of Pneumocystis carinii after effective treatment of P. carinii pneumonia is not related to relapse or survival among patients infected with human immunodeficiency virus. Clin Infect Dis 1998; 26: 509-510.
120. Fassas AB, Bolaños-Meade J, Buddharaju LN et al. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol 2001; 112: 237-241.
121. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Clin Infect Dis 2007; 45: 1161-1170.
122. Post MJ, Lass-Floerl C, Gastl G, Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients. Transpl Infect Dis 2007; 9: 189-195.
123. Reich G, Mapara MY, Reichardt P et al. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2001; 27: 525-529.
124. Hyle EP, Lipworth AD, Zaoutis TE et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamaseproducing enterobacteriaceae: variability by site of infection. Arch Intern Med 2005; 165: 1375-1380.
125. Garnacho-Montero J, Sa-Borges M, Sole-Violan J et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35: 1888-1895.
126. Park SY, Park HJ, Moon SM et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect Dis 2012; 12: 308.
127. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519-527.
128. Vidaur L, Sirgo G, Rodríguez AH, Rello J. Clinical approach to the patient with suspected ventilator-associated pneumonia. Respir Care 2005; 50: 965-974.
129. Chatzinikolaou I, Abi-Said D, Bodey GP et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160: 501-509.
130. Peña C, Suarez C, Ocampo-Sosa A et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis 2013; 57: 208-216.
131. Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents 2013; 41: 301-310.
132. Michalopoulos A, Kasiakou SK, Mastora Z et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9: R53-R59.
133. Aisenberg G, Rolston KV, Dickey BF et al. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis 2007; 26: 13-20.
134. Tada K, Kurosawa S, Hiramoto N et al. Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage. Bone Marrow Transplant 2013; 48: 74-79.
135. Tekçe YT, Erbay A, Cabadak H, Sen S. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother 2012; 24: 150-154.
136. Carroll KC, Cohen S, Nelson R et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 1998; 32: 229-235.
137. Kalil AC, Klompas M, Haynatzki G, Rupp ME. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 2013; 3: e003912.
138. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011; 139: 1148-1155.
139. Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-1797.
140. Faguer S, Kamar N, Fillola G et al. Linezolid-related pancytopenia in organtransplant patients: report of two cases. Infection 2007; 35: 275-277.
141. Silverman JA, Mortin LI, Vanpraagh AD et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-2152.
142. Mori T, Kato J. Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int J Hematol 2010; 91: 588-595.
143. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48: 199-226.
144. Limper AH, Knox KS, Sarosi GA et al. American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183: 96-128.
145. Mousset S, Buchheidt D, Heinz W et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014; 93: 13-32.
146. Maschmeyer G, Haas A. Defining clinical failure for salvage studies. Med Mycol 2006; 44: S315-S318.
147. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-683.
148. Marr KA, Schlamm H, Rottinghaus ST et al. A Randomised, Double-Blind Study of Combination Antifungal Therapy with Voriconazole and Anidulafungin Versus Voriconazole Monotherapy for Primary Treatment of Invasive Aspergillosis. In: 22nd European Congress of Clinical Microbiology and Infectious Diseases, London, UK, 31 March-3 April 2012, abstr #LB2812.
149. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364-371.
150. Spellberg B, Ibrahim A, Roilides E et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis 2012; 54(Suppl 1): S73-S78.
151. Spellberg B, Ibrahim AS, Chin-Hong PV et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67: 715-722.
152. Asai N, Motojima S, Ohkuni Y et al. Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection. J Infect Chemother 2012; 18: 898-905.
153. Li MC, Lee NY, Lee CC et al. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIVinfected individuals. J Microbiol Immunol Infect 2014; 47: 42-47.
154. Dini L, du Plessis M, Frean J, Fernandez V. High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneumonia in South Africa. J Clin Microbiol 2010; 48: 2016-2021.
155. Le Gal S, Damiani C, Perrot M et al. Circulation of Pneumocystis dihydropteroate synthase mutants in France. Diagn Microbiol Infect Dis 2012; 74: 119-124.
156. Nahimana A, Rabodonirina M, Zanetti G et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency viruspositive and-negative patients. J Infect Dis 2003; 188: 1017-1023.
157. Queener SF, Cody V, Pace J et al. Trimethoprim resistance of dihydrofolate reductase (DHFR) variants from clinical isolates of Pneumocystis jirovecii. Antimicrob Agents Chemother 2013; 57: 4990-4998.
158. Thomas CF, Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350: 2487-2498.
159. Smego RA, Jr, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med 2001; 161: 1529-1533.
160. Hughes WT, Rivera GK, Schell MJ et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987; 316: 1627-1632.
161. Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992; 327: 1836-1841.
162. Delclaux C, Zahar JR, Amraoui G et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virusinfected patients. Clin Infect Dis 1999; 29: 670-672.
163. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113: 1215-1224.
164. Moon SM, Kim T, Sung H et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 2011; 55: 4613-4618.
165. Lemiale V, Debrumetz A, Delannoy A et al. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res 2013; 14: 87.
166. Azoulay E, Mokart D, Pène F et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium-a groupe de recherche respiratoire en reanimation oncohematologique study. J Clin Oncol 2013; 31: 2810-2818.
167. Bird GT, Farquhar-Smith P, Wigmore T et al. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. Br J Anaesth 2012; 108: 452-459.
168. Taccone FS, Artigas AA, Sprung CL et al. Characteristics and outcomes of cancer patients in European ICUs. Crit Care 2009; 13: R15.
169. Cherif H, Martling CR, Hansen J et al. Predictors of short and long-term outcome in patients with hematological disorders admitted to the intensive care unit for a life-threatening complication. Support Care Cancer 2007; 15: 1393-1398.
170. Maschmeyer G, Bertschat FL, Moesta KT et al. Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period. Eur J Cancer 2003; 39: 783-792.
171. Owczuk R, Wujtewicz MA, Sawicka W et al. Patients with haematological malignancies requiring invasive mechanical ventilation: differences between survivors and non-survivors in intensive care unit. Support Care Cancer 2005; 13: 332-338.
172. Burghi G, Lemiale V, Seguin A et al. Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis. Intensive Care Med 2011; 37: 1605-1612.
173. Sculier JP. Intensive care and oncology. Support Care Cancer 1995; 3: 93-105.